Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Study summary

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNivolumab and Sitravatinib

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 30, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?261 U.S. locations

Locations may change over time.

Who runs it?Mirati Therapeutics Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Mirati Therapeutics Inc.
Interventions being studied: Biological: Nivolumab; Drug: Sitravatinib; Drug: Docetaxel

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Immunotherapy→Chemotherapy→

Study topics

After prior treatment→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosis of Non-Squamous Non-Small Cell Lung Cancer
Receipt of at least one but not more than two prior treatment regimens in the advanced setting
Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)
Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment
Candidate to receive docetaxel as second or third line therapy

Reasons someone may not be able to joinExclusion criteria

Uncontrolled brain metastases
Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions
Unacceptable toxicity with prior checkpoint inhibitor therapy
Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy
Impaired heart function

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Local Institution - 005-164Birmingham, Alabama
Clearview Cancer Institute - HuntsvilleHuntsville, Alabama
Palo Verde Cancer Specialists - GlendaleGlendale, Arizona
The Oncology Institute of Hope & Innovation - TucsonTucson, Arizona
Yuma Regional Medical CenterYuma, Arizona
Local Institution - 005-174Jonesboro, Arkansas
NEA Baptist Fowler Family Center for Cancer CareJonesboro, Arkansas
Highlands Oncology Group - SpringdaleSpringdale, Arkansas
Comprehensive Blood and Cancer Center - BakersfieldBakersfield, California
Local Institution - 005-118Beverly Hills, California
Local Institution - 005-171Fresno, California
Providence Medical Foundation - Virginia K. Crosson Cancer Center - FullertonFullerton, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 30, 2026. Always confirm current availability with the study team.

View original record ↗